- Home
- Publications
- Publication Search
- Publication Details
Title
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
Authors
Keywords
Tie2 inhibition, Angiopoietin inhibition, Angiogenesis, Anti-angiogenic therapy
Journal
Current Oncology Reports
Volume 21, Issue 3, Pages -
Publisher
Springer Nature
Online
2019-02-26
DOI
10.1007/s11912-019-0771-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
- (2018) David M. Hyman et al. CLINICAL CANCER RESEARCH
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
- (2017) Christian Marth et al. EUROPEAN JOURNAL OF CANCER
- Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice
- (2017) Laura Tuppurainen et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
- (2017) Allison S. Harney et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Anti-angiogenic agents in ovarian cancer: past, present, and future
- (2016) B. J. Monk et al. ANNALS OF ONCOLOGY
- Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
- (2016) Cong Zhou et al. BRITISH JOURNAL OF CANCER
- Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
- (2016) Jin-Sung Park et al. CANCER CELL
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
- (2016) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
- (2016) Jorge Cortes et al. HAEMATOLOGICA
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
- (2016) Yuji Piao et al. NEURO-ONCOLOGY
- Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
- (2016) Jorge Cortes et al. HAEMATOLOGICA
- VEGF and Intraocular Neovascularization: From Discovery to Therapy
- (2016) Napoleone Ferrara Translational Vision Science & Technology
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)
- (2015) Claudia Marchetti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
- (2015) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- (2015) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA
- (2015) A. S. Harney et al. Cancer Discovery
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
- (2014) A. Backen et al. CLINICAL CANCER RESEARCH
- A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
- (2014) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
- (2014) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- (2013) M Peeters et al. BRITISH JOURNAL OF CANCER
- TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2-Expressing Monocytes in Human Breast Tumors
- (2013) M. Ibberson et al. CLINICAL CANCER RESEARCH
- A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2013) David S. Hong et al. Clinical Genitourinary Cancer
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
- (2012) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617
- (2012) Nikolett Molnar et al. MICROVASCULAR RESEARCH
- Multiple Effects of Angiopoietin-2 Blockade on Tumors
- (2011) Claire E. Lewis et al. CANCER CELL
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More